Literature DB >> 32040618

Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma.

Yoh Asahi1, Kanako C Hatanaka2, Yutaka Hatanaka3, Toshiya Kamiyama1, Tatsuya Orimo1, Shingo Shimada1, Akihisa Nagatsu1, Yuzuru Sakamoto1, Hirofumi Kamachi1, Nozomi Kobayashi1, Moto Fukai1, Akinobu Taketomi4.   

Abstract

PURPOSE: A lack of effective systemic therapy is one reason for the poor prognosis of intrahepatic cholangiocarcinoma. Newly developed immune checkpoint inhibitors function by minimizing CD8+ T cell suppression to improve tumor-specific responses. This study aimed to examine the characteristics of CD8+ T cells in intrahepatic cholangiocarcinoma.
METHODS: Clinicopathological data, including the overall survival, of 69 cases of postoperative intrahepatic cholangiocarcinoma were prospectively investigated. We then immunohistochemically stained for CD8, Foxp3, CD163, PD-L1, and human leukocyte antigen (HLA) class I and counted the number of CD8+ T cells, Foxp3+ T cells, and CD163+ macrophages in different areas (outer border, interborder, and intratumor).
RESULTS: A significant difference was found in the 5-year overall survival between the CD8+ T cell high group (45.5%) and low group (24.7%) in the outer border area (p = 0.0103). Furthermore, the number of CD8+ T cells and the high expression of HLA class I were positively correlated (p = 0.0341).
CONCLUSION: The number of CD8+ T cells in the outer border area of the tumor correlated with the HLA class I expression of intrahepatic cholangiocarcinoma and may therefore be a prognostic factor for patients with postoperative intrahepatic cholangiocarcinoma.

Entities:  

Keywords:  CD8+ T cell; Cholangiocarcinoma; HLA class I; Intrahepatic cholangiocarcinoma; PD-L1

Year:  2020        PMID: 32040618     DOI: 10.1007/s00595-020-01967-y

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  12 in total

Review 1.  Cholangiocarcinoma: An Emerging Target for Molecular Therapy.

Authors:  Ilya Tsimafeyeu; Mark Temper
Journal:  Gastrointest Tumors       Date:  2021-07-21

2.  Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma.

Authors:  Chuan Lan; Yuki Kitano; Yo-Ichi Yamashita; Takanobu Yamao; Kiyoshi Kajiyama; Tomoharu Yoshizumi; Kengo Fukuzawa; Keishi Sugimachi; Yasuharu Ikeda; Hiroshi Takamori; Nobutomo Miyanari; Masahiko Hirota; Hideo Baba
Journal:  Br J Cancer       Date:  2021-10-06       Impact factor: 9.075

3.  A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.

Authors:  Cecilia Monge; Erica C Pehrsson; Changqing Xie; Austin G Duffy; Donna Mabry; Bradford J Wood; David E Kleiner; Seth M Steinberg; William D Figg; Bernadette Redd; Anuradha Budhu; Sophie Wang; Mayank Tandon; Lichun Ma; Xin Wei Wang; Tim F Greten
Journal:  Oncologist       Date:  2022-03-11

4.  Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers.

Authors:  Jun Zhang; Zhenru Wu; Xin Zhang; Siyun Liu; Jian Zhao; Fang Yuan; Yujun Shi; Bin Song
Journal:  ESMO Open       Date:  2020-11

5.  Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma.

Authors:  Hong Wu; Yulong Wei; Mei Jian; Hong Lu; Qingzhu Song; Liheng Hao; Yong Yue
Journal:  Onco Targets Ther       Date:  2021-01-06       Impact factor: 4.147

6.  Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.

Authors:  Kyohei Yugawa; Shinji Itoh; Norifumi Iseda; Takeshi Kurihara; Yoshiyuki Kitamura; Takeo Toshima; Noboru Harada; Kenichi Kohashi; Shingo Baba; Kousei Ishigami; Yoshinao Oda; Tomoharu Yoshizumi; Masaki Mori
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

7.  Immune Score Predicts Outcomes of Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy.

Authors:  Wei Zou; Meng-Long Zhou; Ling-Yi Zhang; Jia-Ning Yang; Wang Yang; Ya-Qi Wang; Yu-Xi Yi; Gui-Chao Li; Zhen Zhang
Journal:  J Oncol       Date:  2021-12-27       Impact factor: 4.375

8.  Developing metabolic gene signatures to predict intrahepatic cholangiocarcinoma prognosis and mining a miRNA regulatory network.

Authors:  Xun Ran; Jun Luo; Chaohai Zuo; YongYe Huang; Yi Sui; JunHua Cen; Shengli Tang
Journal:  J Clin Lab Anal       Date:  2021-12-06       Impact factor: 2.352

Review 9.  The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.

Authors:  Dong Liu; Lara Rosaline Heij; Zoltan Czigany; Edgar Dahl; Sven Arke Lang; Tom Florian Ulmer; Tom Luedde; Ulf Peter Neumann; Jan Bednarsch
Journal:  J Exp Clin Cancer Res       Date:  2022-04-07

Review 10.  Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells.

Authors:  Michela Anna Polidoro; Joanna Mikulak; Valentina Cazzetta; Ana Lleo; Domenico Mavilio; Guido Torzilli; Matteo Donadon
Journal:  World J Gastroenterol       Date:  2020-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.